Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia

M. Jesenak, V. Vanecek, M. Ondrusova, V. Urdova, K. Dostalova, L. Hochmuth

. 2023 ; 167 (3) : 272-280. [pub] 20230710

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23018194

AIMS: Mepolizumab, a fully-humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5, has shown improved asthma control and lung function in randomised controlled trials. The aim of this study was to evaluate real-world clinical experience in patients with severe eosinophilic asthma treated with mepolizumab in Slovakia. METHODS: A retrospective, non-interventional study based on medical records of all adult asthma patients initiating mepolizumab between November 1, 2017 and January 31, 2019, completing 12 months of treatment. At baseline, general and clinical profile data were recorded 12 months prior to treatment. Primary and secondary endpoints described the results of mepolizumab use at 2, 6, and 12 months after the initiation and compared to baseline. Statistical testing of individual change (in each patient) in selected parameters was performed. RESULTS: The cohort included 17 patients with particularly severe asthma at baseline, with frequent severe exacerbations (SE, median 5 [IQR 4-6]/patient/year), high blood eosinophil counts (median 0.6x109/L), frequent oral corticosteroid (OCS) dependence (82.35%), median dose 15 (IQR 7.5-20) mg/day, impaired lung function, and a spectrum of comorbidities. In a one-year follow-up, the data showed reductions in median SE (0 [IQR 0-1] patient/year, eosinophilia (median 0.175x109/L) and OCS maintenance dose (median 6.25 [IQR 2.5-20] mg/day), all statistically significant after 12 months on mepolizumab. Improved and stabilised lung functions throughout the cohort and a reduced incidence of nasal polyposis were observed. CONCLUSIONS: The results provide clinical evidence of mepolizumab efficacy in a real sample of patients with severe asthma when administered in routine care settings in Slovakia.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23018194
003      
CZ-PrNML
005      
20231121092152.0
007      
ta
008      
231107s2023 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2023.029 $2 doi
035    __
$a (PubMed)37439266
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Jeseňák, Miloš, $u Department of Clinical Immunology and Allergology, University Teaching Hospital in Martin, Martin, Slovakia $u Department of Pulmonology and Phthisiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Teaching Hospital in Martin, Martin, Slovakia $u Department of Paediatrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Teaching Hospital in Martin, Martin, Slovakia $d 1980- $7 xx0104191
245    10
$a Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia / $c M. Jesenak, V. Vanecek, M. Ondrusova, V. Urdova, K. Dostalova, L. Hochmuth
520    9_
$a AIMS: Mepolizumab, a fully-humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5, has shown improved asthma control and lung function in randomised controlled trials. The aim of this study was to evaluate real-world clinical experience in patients with severe eosinophilic asthma treated with mepolizumab in Slovakia. METHODS: A retrospective, non-interventional study based on medical records of all adult asthma patients initiating mepolizumab between November 1, 2017 and January 31, 2019, completing 12 months of treatment. At baseline, general and clinical profile data were recorded 12 months prior to treatment. Primary and secondary endpoints described the results of mepolizumab use at 2, 6, and 12 months after the initiation and compared to baseline. Statistical testing of individual change (in each patient) in selected parameters was performed. RESULTS: The cohort included 17 patients with particularly severe asthma at baseline, with frequent severe exacerbations (SE, median 5 [IQR 4-6]/patient/year), high blood eosinophil counts (median 0.6x109/L), frequent oral corticosteroid (OCS) dependence (82.35%), median dose 15 (IQR 7.5-20) mg/day, impaired lung function, and a spectrum of comorbidities. In a one-year follow-up, the data showed reductions in median SE (0 [IQR 0-1] patient/year, eosinophilia (median 0.175x109/L) and OCS maintenance dose (median 6.25 [IQR 2.5-20] mg/day), all statistically significant after 12 months on mepolizumab. Improved and stabilised lung functions throughout the cohort and a reduced incidence of nasal polyposis were observed. CONCLUSIONS: The results provide clinical evidence of mepolizumab efficacy in a real sample of patients with severe asthma when administered in routine care settings in Slovakia.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a antiastmatika $x terapeutické užití $7 D018927
650    _2
$a retrospektivní studie $7 D012189
650    12
$a bronchiální astma $x farmakoterapie $x komplikace $7 D001249
650    12
$a eozinofilie $x komplikace $x farmakoterapie $7 D004802
650    _2
$a hormony kůry nadledvin $x terapeutické užití $7 D000305
651    _2
$a Slovenská republika $7 D018154
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vaněček, Václav $u GlaxoSmithKline, Medical Department, Prague, Czech Republic $7 xx0246192
700    1_
$a Ondrušová, Martina $u Pharm-In, Ltd, Bratislava, Slovakia $u Faculty of Public Health, Slovak Medical University, Bratislava, Slovakia $7 xx0078815
700    1_
$a Urdova, Veronika $u Department of Pulmonology and Phthisiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Teaching Hospital in Martin, Martin, Slovakia $u Allergology and Immunology Clinic, Department of Internal Medicine, F. D. Roosevelt Hospital, Banska Bystrica, Slovakia
700    1_
$a Dostálová, Katarína $u Pulmonology Outpatient Clinic Rockmed, Bratislava, Slovakia $7 xx0076652
700    1_
$a Hochmuth, Luděk $u Allergology and Immunology Clinic, Department of Internal Medicine, F. D. Roosevelt Hospital, Banska Bystrica, Slovakia $7 xx0231031
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 167, č. 3 (2023), s. 272-280
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37439266 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20231107 $b ABA008
991    __
$a 20231121092149 $b ABA008
999    __
$a ok $b bmc $g 2011495 $s 1204597
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 167 $c 3 $d 272-280 $e 20230710 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK198 $a Pubmed-20231107

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace